Literature DB >> 19615906

Neurofibroma development in NF1--insights into tumour initiation.

Simona Parrinello1, Alison C Lloyd.   

Abstract

Dissecting the early steps of tumourigenesis is key to our understanding of cancer biology. However, lack of knowledge of initiating mutations and the target 'cell of origin' has slowed progress towards this goal. Genetically engineered mouse models of the tumour-predisposition syndrome neurofibromatosis type-1 provide a rare opportunity to study tumour initiation resulting from a known genetic change in a known cell type. Recent exciting work using these models now sheds more light onto early tumourigenesis. Here, we discuss the studies that have identified mature differentiated Schwann cells as the cell of origin and revealed the molecular and cellular mechanisms of neurofibroma initiation. A novel dual and opposing role for the microenvironment, from pro-differentiative to pro-carcinogenic, has emerged.

Entities:  

Mesh:

Year:  2009        PMID: 19615906     DOI: 10.1016/j.tcb.2009.05.003

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  13 in total

1.  Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Authors:  Laura Thomas; Lan Kluwe; Nadia Chuzhanova; Victor Mautner; Meena Upadhyaya
Journal:  Neurogenetics       Date:  2010-04-01       Impact factor: 2.660

2.  Sustained activation of ERK1/2 MAPK in Schwann cells causes corneal neurofibroma.

Authors:  Paola Bargagna-Mohan; Akihiro Ishii; Ling Lei; Daniel Sheehy; Saagar Pandit; Grace Chan; Rashmi Bansal; Royce Mohan
Journal:  J Neurosci Res       Date:  2017-05-10       Impact factor: 4.164

3.  Partial Blindness to Submicron Topography in NF1 Haploinsufficient Cultured Fibroblasts Indicates a New Function of Neurofibromin in Regulation of Mechanosensoric.

Authors:  D Kaufmann; J Hoesch; Y Su; L Deeg; K Mellert; J P Spatz; R Kemkemer
Journal:  Mol Syndromol       Date:  2012-09-27

4.  Axon contact-driven Schwann cell dedifferentiation.

Authors:  Jennifer Soto; Paula V Monje
Journal:  Glia       Date:  2017-02-24       Impact factor: 7.452

Review 5.  Plastic fantastic: Schwann cells and repair of the peripheral nervous system.

Authors:  Haesun A Kim; Thomas Mindos; David B Parkinson
Journal:  Stem Cells Transl Med       Date:  2013-07-01       Impact factor: 6.940

6.  Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets.

Authors:  Songjian Lu; Kevin N Lu; Shi-Yuan Cheng; Bo Hu; Xiaojun Ma; Nicholas Nystrom; Xinghua Lu
Journal:  PLoS Comput Biol       Date:  2015-08-28       Impact factor: 4.475

7.  Restoring functional neurofibromin by protein transduction.

Authors:  K Mellert; S Lechner; M Lüdeke; M Lamla; P Möller; R Kemkemer; K Scheffzek; D Kaufmann
Journal:  Sci Rep       Date:  2018-04-18       Impact factor: 4.379

8.  HDAC3 Regulates the Transition to the Homeostatic Myelinating Schwann Cell State.

Authors:  Laura H Rosenberg; Anne-Laure Cattin; Xavier Fontana; Elizabeth Harford-Wright; Jemima J Burden; Ian J White; Jacob G Smith; Ilaria Napoli; Victor Quereda; Cristina Policarpi; Jamie Freeman; Robin Ketteler; Antonella Riccio; Alison C Lloyd
Journal:  Cell Rep       Date:  2018-12-04       Impact factor: 9.423

9.  Neurofibromin Deficiency and Extracellular Matrix Cooperate to Increase Transforming Potential through FAK-Dependent Signaling.

Authors:  Andrea Errico; Anna Stocco; Vincent M Riccardi; Alberto Gambalunga; Franco Bassetto; Martina Grigatti; Amedeo Ferlosio; Gianluca Tadini; Debora Garozzo; Stefano Ferraresi; Andrea Trevisan; Sandra Giustini; Andrea Rasola; Federica Chiara
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  Secretome survey of human plexiform neurofibroma derived Schwann Cells reveals a secreted form of the RARRES1 protein.

Authors:  Hui-Ling Chen; Haeri Seol; Kristy Jean Brown; Heather Gordish-Dressman; Ashley Hill; Vittorio Gallo; Roger Packer; Yetrib Hathout
Journal:  Int J Mol Sci       Date:  2012-07-24       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.